Understanding injectable poly-L-lactic acid

Cosmetic Dermatology

Volumn 20, Issue 6, 2007, Pages 388-392

  Butterwick, Kimberly ^a,b,c,d  

^a Dermatology & Cosmetic Laser Associates of La Jolla   (United States)

^b Medicis Pharmaceutical Corporation   (United States)

^c Dermik Laboratories   (United States)

^d ALLERGAN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; COLLAGEN; LIDOCAINE; POLYLACTIC ACID;

AGING; DEVICE; ESTHETICS; FACE; HUMAN; INJECTION SITE CONTUSION; INJECTION SITE DISCOMFORT; INJECTION SITE EDEMA; INJECTION SITE PAIN; LIPOATROPHY; NEEDLE; OUTCOME ASSESSMENT; PAPULE; REVIEW; RHYTIDOPLASTY; SAFETY; SKIN ATROPHY; TREATMENT INDICATION; WRINKLE;

EID: 34250828488     PISSN: 10413766     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (18)

1. Werschler WP, Weinkle S. Longevity of effects of injectable products for soft-tissue augmentation. J Drugs Dermatol. 2005;4:20-27.
2. Simamora P, Chern W. Poly-L-laclic acid: an overview. J Drugs Dermatol. 2006;5:436-440.
3. Gogolewski S, Jovanovic M, Perren SM, et al. Tissue response and in vivo degradation of selected polyhydroxyacids: polylactides (PLA), poly(3-hydroxybutyrate) (PHB), and poly(3-hydroxybutyrate-co-3-hydroxyvalerate) (PHB/VA). J Biomed Mater Res. 1993;27:1135-1148.
4. Kronenthal RL. Biodegradable polymers in medicine. In: Kronenthal RL, Oser Z, Martin E, eds. Polymers in Science and Surgery. New York, NY: Plenum Press; 1975:119-137.
5. Polymer Science and Technology; vol 8.
6. Valantin MA, Aubron-Olivier C, Ghosn J, et al. Polylactic acid implants (New-Fill) to correct facial lipoatrophy in HIV-infected patients: results of the open-label study VEGA. AIDS. 2003;17:2471-2477.
7. Bauer U. Improvement of facial aesthetics at 40 months with injectable poly-L-lactic acid (PLLA). Presented at: 17th Congress of the International Society of Aesthetic Plastic Surgery; August 28-31, 2004; Houston, Tex.
8. Lemperle G, Morhenn V, Charrier U. Human histology and persistence of various injectable filler substances for soft tissue augmentation. Aesthetic Plast Surg. 2003;27:354-366.
9. Lowe NJ, Maxwell CA, Patnaik R. Adverse reactions to dermal fillers: review. J Derm Surg. 2005;31:1616-1625.
10. Moyle GJ, Lysakova L, Brown S, et al. A randomized open-label study of immediate versus delayed polylactic acid injections for the cosmetic management of facial lipoatrophy in persons with HIV infection. HIV Med. 2004;5:82-87.
11. Sculptra [package insert] Berwyn, Pa: Dermik Laboratories; 2006.
12. Vleggaar D, Bauer U. Facial enhancement and the European experience with Sculptra (poly-L-lactic acid). J Drugs Dermatol. 2004;3:542-547.
13. Burgess CM, Quiroga RM. Assessment of the safety and efficacy of poly-L-lactic acid for the treatment of HIV-associated facial lipoatrophy. J Am Acad Dermatol. 2005;52:233-239.
14. Vleggaar D, Forte R. Cosmetic injectable devices: a review of the injection techniques. J Drugs Dermatol. 2006;5:951-956.
15. Vleggaar D. Poly-L-lactic acid: consultation on the injection techniques. J Eur Acad Dermatol Venereol. 2006;20(suppl 1):17-21.
16. Duffy DM. Complications of fillers: overview. Dermatol Surg. 2005;31:1626-1633.
17. Engelhard P, Humble G, Mest D. Safety of Sculptra: a review of clinical trial data. J Cosmet Laser Ther. 2005;7:201-205.
18. Woerle B, Hanke CW, Sattler G. Poly-L-lactic acid: a temporary filler for soft tissue augmentation. J Drugs Dermatol. 2004;3:385-389.